Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype  by Rettberg, Jamaica R. et al.
lable at ScienceDirect
Neurobiology of Aging 40 (2016) 155e163Contents lists avaiNeurobiology of Aging
journal homepage: www.elsevier .com/locate/neuagingIdentifying postmenopausal women at risk for cognitive
decline within a healthy cohort using a panel of clinical
metabolic indicators: potential for detecting an
at-Alzheimer’s risk metabolic phenotype
Jamaica R. Rettberg a, Ha Dang b, Howard N. Hodis b,c,d, Victor W. Henderson e,f,
Jan A. St. John b,c, Wendy J. Mack b,c, Roberta Diaz Brinton a,d,g,*
aNeuroscience Department, University of Southern California, Los Angeles, CA, USA
bDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
cDepartment of Medicine, Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
dDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
eDivision of Epidemiology, Department of Health Research and Policy, Stanford University, Stanford, CA, USA
fDepartment of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA
gDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAa r t i c l e i n f o
Article history:
Received 23 August 2015
Received in revised form 8 January 2016
Accepted 21 January 2016
Available online 29 January 2016
Keywords:
Cognitive aging
Metabolism
Biomarker
Alzheimer’s disease
Menopause
Hormone therapy* Corresponding author at: Department of Pharm
Sciences, School of Pharmacy, University of Southern
90033, USA. Tel.: 323 442 1436; fax: 323 442 1470.
E-mail address: rbrinton@usc.edu (R.D. Brinton).
0197-4580/ 2016 The Authors. Published by Elsevier
http://dx.doi.org/10.1016/j.neurobiolaging.2016.01.011a b s t r a c t
Detecting at-risk individuals within a healthy population is critical for preventing or delaying Alzheimer’s
disease. Systemsbiology integrationof brain andbodymetabolismenables peripheralmetabolic biomarkers
to serve as reporters of brain bioenergetic status. Using clinical metabolic data derived from healthy post-
menopausalwomen in theEarlyversus Late InterventionTrialwith Estradiol (ELITE),we conductedprincipal
components and k-means clustering analyses of 9 biomarkers to deﬁne metabolic phenotypes. Metabolic
clusters were correlated with cognitive performance and analyzed for change over 5 years. Metabolic bio-
markers at baseline generated 3 clusters, representing womenwith healthy, high blood pressure, and poor
metabolic phenotypes. Compared with healthy women, poor metabolic women had signiﬁcantly lower
executive, global and memory cognitive performance. Hormone therapy provided metabolic beneﬁt to
women in high blood pressure and poor metabolic phenotypes. This panel of well-established clinical pe-
ripheral biomarkers represents an initial step toward developing an affordable, rapidly deployable, and
clinically relevant strategy to detect an at-risk phenotype of late-onset Alzheimer’s disease.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Effective prevention and delay of Alzheimer’s disease (AD) will
require intervention during the preclinical phase (Carrillo et al.,
2013; Jack et al., 2011; Sperling et al., 2011; Yao et al., 2011).
Achievement of this goal entails accurate identiﬁcation of at-risk
individuals before clinically symptomatic disease. Successful
screening of at-risk populations requires an accurate, rapidly
deployable, clinically accessible, and economically feasible
biomarker strategy. To achieve these criteria, biomarkers based on
peripheral indicators that accurately predict early risk status of theacology and Pharmaceutical
California, Los Angeles, CA,
Inc. This is an open access article ubrain would be advantageous. Interrogating the metabolic system
through peripheral indicators provides one such strategy, as sub-
stantial evidence supports the hypothesis that midlife metabolism
affects cognitive health in older age (Cheng et al., 2012; Gottesman
et al., 2014; Kenna et al., 2013; Kivipelto et al., 2001; Norton et al.,
2014; Rawlings et al., 2014; Roberts et al., 2014; Wharton et al.,
2014; Whitmer et al., 2005).
One strategy to enrich an at-risk population for biomarker
development is to focus on individuals with a greater lifetime risk
of AD. Women have a 2-fold greater lifetime risk of developing AD,
and thus, constitute a target population for which biomarkers for
early detection of risk could have substantial public health impact
(Alzheimer’s Association, 2014). Although the biological basis for
gender differences in AD remains to be established, basic and
clinical science indicate that the menopausal transition and decline
in estrogen can adversely affect brain and whole-body metabolismnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014; Yin et al., 2015).
Based on basic and clinical science, we hypothesized that
metabolically based biomarkers would identify individuals at the
tipping point for developing an at-risk for Alzheimer’s phenotype
in a population of healthy postmenopausal women. To test this
hypothesis, we conducted a clustering analysis using baseline data
from the Early versus Late Intervention Trial with Estradiol (ELITE;
Hodis et al., 2015) to identify metabolic phenotypes. We subse-
quently investigated the association of these phenotypes with
cognitive performance and the longitudinal change in both meta-
bolic phenotypes and cognitive performance over 5 years. We
further hypothesized that the administration of hormone therapy
(HT) would differentially impact both overall metabolism and
cognitive performance within women of different metabolic
phenotypes.2. Methods
2.1. The ELITE clinical trial
ELITE was a double-blinded, placeboecontrolled clinical trial
randomizing 643 postmenopausal women. It was designed to test
the timing hypothesis of postmenopausal HT, such that HT beneﬁts
and risks depend on the temporal initiation of HT relative to time-
since-menopause, which is in turn related to underlying tissue
health (Henderson et al., 2013; Karim et al., 2015). Women were
recruited into 2 cohorts: early menopause (n ¼ 271), deﬁned as
within 6 years of menopause, and late menopause (n ¼ 372),
deﬁned as 10 or more years postmenopause.
Eligible women were postmenopausal, deﬁned as absence of
menses for 6 months or surgical menopause and serum estradiol
below 25 pg/mL. Of the women included, 14 were between
6 months and 1 year postmenopausal, and the remainder were all
>1 year postmenopausal. Womenwere excluded if they had clinical
signs, symptoms, or personal history of cardiovascular disease;
diabetes mellitus (fasting serum glucose 140 mg/dL); uncon-
trolled hypertension (diastolic blood pressure 110 mmHg);
untreated thyroid disease; plasma triglyceride levels >500 mg/dL;
serum creatinine >2.0 mg/dL; cirrhosis or liver disease; a life
threatening disease with prognosis <5 years; or inability to deter-
mine time-since-menopause. Women with a history of deep vein
thrombosis, pulmonary embolism, or breast cancer were excluded.
Within each postmenopause cohort, women were randomized to
receive either HT (17b-estradiol, 1 mg daily) or placebo. Women
who had not undergone a hysterectomy also used vaginal 4% pro-
gesterone (or placebo) gel for the last 10 days of each month.
The primary trial outcome was rate of change of distal common
carotid artery far wall intima-media thickness (Hodis et al., 2015).
A secondary outcome was change in cognitive function (Henderson
et al., 2013). A comprehensive battery of neuropsychological tests
was administered before randomization, at about 2.5 years, and at
each participant’s ﬁnal study visit, approximately 5 years after
randomization. The battery included 14 neuropsychological tests
that emphasized standardized tests sensitive to age-associated
change in middle-aged and older adults (Henderson et al., 2013).
ELITE was approved by the Institutional Review Board of the
University of Southern California. All participants provided written
informed consent.
For the longitudinal analysis, the full sample of 643 women was
restricted to those completing cognitive testing at baseline and
again at either 2.5 years, 5 years, or both (n ¼ 502). Of the 502
women, 216 were in the early menopause and 286 in the late
menopause groups.2.2. Clinical and laboratory measurements
At each 6-month clinic visit, 8-hour fasting blood was drawn,
and blood pressure was measured. Current medication use was
recorded. Samples were prepared and stored at 70 C.
Fasting glucose, b-hydroxybutyrate, and insulin were measured
in stored plasma using kits (glucose and b-hydroxybutyrate:
Cayman Chemical, Ann Arbor, MI, USA; insulin: Alpco Diagnostics,
Salem, NH, USA), according to eachmanufacturer’s protocol. Fasting
total cholesterol, triglycerides, and high-density lipoprotein (HDL)
cholesterol levels were measured in fresh plasma using an enzy-
matic method of the Standardization Program of the National
Centers for Disease Control and Prevention as described previously
(Hodis et al., 2015). Low-density lipoprotein (LDL) cholesterol was
computed using the Friedewald equation (Friedewald et al., 1972).
Fasting HbA1c was measured in fresh whole blood using Bio-Rad
Hemoglobin A1c high performance liquid chromatography.
2.3. Statistical analysis
The analysis included 9 metabolic variables: glucose, the homeo-
staticmodelassessmentscore (HOMA;ameasureof insulinresistance:
[glucose mmol/L  insulin]/22.5), ketones (b-hydroxybutyrate), HDL
cholesterol, LDL cholesterol, triglycerides, HbA1c, and systolic and
diastolic blood pressure (SBP, DBP). These biomarkers were
selected on the basis of their contribution to metabolic, cardio-
vascular, and neurologic health. Insulin and total cholesterol were
excluded as these were respectively highly correlated with the
HOMA score (R2¼ 0.98, p< 0.0001) and LDL cholesterol (R2¼ 0.89,
p < 0.0001). All variables were standardized using baseline aver-
ages and standard deviations from the entire ELITE sample. A
principal components analysis on the 9 standardized variables
identiﬁed the number of potential clusters that best explained the
variance in the dataset. Specifying 3 clusters, a nonhierarchical
K-means clustering algorithm was performed; the resulting 3
clusters were descriptively identiﬁed based on their means proﬁle.
The 3 clusters were compared on demographic factors and meta-
bolic variables using analysis of variance and covariance for
continuous variables and c2 tests for categorical variables.
Three cognitive composite scores (global cognition, executive
functions, and verbal memory) were generated from the 14-item
test battery. Composite scores were a linear sum of the standard-
ized test scores within each domain, with each standard test score
inversely weighted by its correlation with other contributing
cognitive tests (Henderson et al., 2013). The verbal memory com-
posite score was deﬁned a priori by Word List Free Recall (a short
version of the California Verbal Learning Test II) immediate and
delayed recall, and Paragraph Recall (East Boston Memory Test)
immediate and delayed recall (Henderson et al., 2013). Tests
included in the executive functions composite score were Symbol
Digit Modalities Test, Trail Making Test part B, Shipley Abstraction
Scale, and category ﬂuency (Animal Naming). These tests were
determined by a principal components analysis of baseline scores
(Henderson et al., 2013). The composite score for global cognition
was similarly calculated as a weighted average, including all tests in
the battery. Analysis of covariance was used to test for overall cross-
sectional differences among metabolic clusters on each cognitive
composite and test; covariates included postmenopause cohort
(early/late), random intervention assignment, and education.
Measurements of longitudinal change in metabolic biomarkers
usedmeasures at 3 time points (baseline, 2.5 years, and end of study
at approximately 5 years) to match with cognitive assessment times.
Modeling each metabolic biomarker or cognitive composite sepa-
rately as the longitudinal dependent variable, data were analyzed
using mixed effects linear models, testing the effects of baseline
Fig. 1. Cluster development. Women in the healthy metabolic cluster are shown in
green. Women in the high blood pressure cluster are shown in red. Women in the poor
metabolic cluster are shown in blue. Can1, the ﬁrst canonical variable: the linear
combination of the clustering variables that best explains cluster group differences (i.e.,
most correlated with the cluster group). Can2, the second canonical variable: the linear
combination of clustering variables that is most correlated with the cluster groups but
is uncorrelated with Can1. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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change. The regression coefﬁcient for time (years) since randomi-
zation estimated the slope of metabolic/cognitive change (in units/
year). In themixedmodel, random effects were speciﬁed to allow forTable 1
Sample characteristics by cluster
Comparisons between clusters
Healthy metabolic H
(n) 209 (41.6%)
Mean age, years (SD) 60.0 (7.3)
Mean time since menopause, years (SD) 9.9 (7.4)
Mean education, years (SD) 16.4 (2.2)
Menopause cohort
Early menopause, n (%) 95 (45.5)
Late menopause, n (%) 114 (54.5)
Biomarkers
Glucose (mg/dL) 80.60 (7.58)
Insulin resistance (HOMA score) 0.98 (0.48)
Ketones (mM) 0.12 (0.06)
HDL cholesterol (mg/dL) 74.96 (17.88)
LDL cholesterol (mg/dL) 129.95 (29.64)
Triglycerides (mg/dL) 80.41 (26.99)
HbA1c (%) 5.60 (0.38)
Systolic blood pressure (mmHg) 105.83 (8.96)
Diastolic blood pressure (mmHg) 67.95 (5.52)
Race or ethnicity Comparisons between clusters
Healthy metabolic High blood pressure
n, % of cluster % Of racial group n, % of cluster %
White, non-Hispanic 157 (75.1) 44.2 140 (73.3)
Black 14 (6.7) 34.1 18 (9.4)
Hispanic 17 (8.1) 27.0 21 (11.0)
Asian 21 (10.1) 48.8 12 (6.3)
Demographics and biomarker values (average, standard deviation) for the 3 phenotypes
Age, years since menopause, and education were compared using ANOVA. Differences
Biomarker results were compared using ANOVA and adjusted for random intervention ass
to adjust for multiple comparisons.
Key: ANOVA, analysis of variance; BP, blood pressure; HOMA, homeostatic model assess
a Average value is signiﬁcantly different from the healthy phenotype (p < 0.05).
b Average value is signiﬁcantly different from the high BP phenotype (p < 0.05).subject-speciﬁc deviations around the average baseline (regression
intercept) and slope of change. Interaction terms ofmetabolic cluster
and treatment condition with time tested whether the slopes
signiﬁcantly differed by these variables. All metabolic analyses
includedmenopause cohort and randomized treatment allocation as
independent variables; all cognitive analyses additionally included
years of education. All statistical tests used anoverall 2-sided alpha of
0.05; post hoc pairwise comparisons corrected for multiple com-
parisons using the TukeyeKramer method. All associations were
evaluated for differences by menopause strata; as no signiﬁcant
differences were found, the analyses for early and late menopause
women were collapsed within each phenotype.3. Results
3.1. Baseline metabolic phenotypes and demographics
The 3 clusters (Fig. 1) were descriptively identiﬁed based on
their mean proﬁle (Table 1): healthy metabolic (n ¼ 209, 41.6%),
high blood pressure (BP; n ¼ 191, 38.1%), and poor metabolic (n ¼
102, 20.3%). Reﬂecting the clustering algorithm, the healthy and
poor metabolic phenotypes signiﬁcantly differed on all metabolic
biomarkers (Table 1). Healthy and high BP phenotypes signiﬁcantly
differed on all biomarkers except glucose and HbA1c; High BP and
poor metabolic signiﬁcantly differed on all biomarkers except
ketones and LDL cholesterol (Table 1). Most of the metabolic
biomarker means were within a normal range, consistent with
recruitment of a healthy population of postmenopausal women.
However, the metabolic biomarker means in the poor metabolic
group were at the margins of clinically healthy values (Table 1).Main effect p-value
igh blood pressure Poor metabolic
191 (38.1%) 102 (20.3%)
60.9 (6.8) 61.1 (6.5) 0.39
10.4 (7.7) 11.5 (8.4) 0.23
16.2 (2.1) 15.7 (2.3)a 0.06
0.48
82 (42.9) 39 (38.2)
109 (57.1) 63 (61.8)
80.28 (7.46) 91.55 (9.77)a,b <0.0001
1.16 (0.46)a,b 2.62 (1.12)a,b <0.0001
0.10 (0.03)a 0.10 (0.04)a 0.0002
65.40 (15.67)a 52.08 (10.77)a,b <0.0001
137.11 (29.11)a 144.96 (33.43)a 0.0009
97.31 (33.36)a 166.59 (65.59)a,b <0.0001
5.52 (0.40) 5.80 (0.45)a,b <0.0001
125.27 (10.26)a 121.18 (10.74)a,b <0.0001
80.86 (5.82)a 76.31 (7.73)a,b <0.0001
Main effect p-value
Poor metabolic
Of racial group n, % of cluster % Of racial group
39.5 58 (56.9) 16.3 0.0014
43.9 9 (8.8) 22.0
33.3 25 (24.5) 39.7
27.9 10 (9.8) 23.3
.
between clusters on menopause cohort and race were assessed using c2 analysis.
ignment andmenopause cohort (early vs. late). The TukeyeKramermethodwas used
ment; SD, standard deviation.
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menopause, or postmenopause cohort (early and/or late; Table 1).
Women in the healthy phenotype had on average 7moremonths of
education relative to the poormetabolic phenotype (p¼ 0.045). The
race and/or ethnic distribution signiﬁcantly differed across clusters
(p¼ 0.0014); Caucasian (44%) and Asian (49%) women had a greater
likelihood of membership in the healthy metabolic phenotype.
African American women had greater likelihood of membership in
the high BP phenotype (44%), whereas Hispanic women were most
represented in the poor metabolic phenotype (40%).3.2. Baseline cognitive performance
Cognitive test comparisons were initially adjusted for postmen-
opause cohort (early vs. late menopause) and random intervention
assignment. After these adjustments, the phenotypes signiﬁcantly
differed on global cognition (p ¼ 0.020), verbal memory (p ¼ 0.013),
and executive functions (p ¼ 0.019). Women in the healthy pheno-
type performed signiﬁcantly better than women in the poor meta-
bolic phenotype on global cognition (p ¼ 0.015), verbal memory
(p ¼ 0.009), and executive functions (p ¼ 0.015; Fig. 2A). Women in
the healthy versus high BP phenotypes, and women in the high BP
versus poor metabolic phenotypes, did not signiﬁcantly differ on
cognitive performance. With additional adjustment for education, Adjusted for menopause cohort 
and randomized intervention
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A
Fig. 2. Comparison of cognitive composite scores between phenotypes at baseline. Signiﬁcan
verbal memory, and executive functions. (A) Results after adjusting for menopause cohort and
*p < 0.05. Error bars represent SEM. The TukeyeKramer method was used to adjust for mulcluster groups did not signiﬁcantly differ on global cognition
(p¼ 0.085) and executive functions (p¼ 0.089); group differences on
verbal memory remained statistically signiﬁcant (p ¼ 0.037), with
verbalmemory signiﬁcantly different betweenwomen in the healthy
and poor metabolic phenotypes (p ¼ 0.028; Fig. 2B).3.3. Effect of aging on metabolic biomarkers and cognition
We initially evaluated the impact of aging over the 5-year trial
among the women randomized to placebo using mixed effects
models. All women showed a signiﬁcant amount of metabolic
change regardless of metabolic phenotype (Table 2A, showing
mean [standard error of the mean] estimates of annual change).
Three metabolic biomarkers, HbA1c, HDL cholesterol, and LDL
cholesterol, showed changes that can be considered predominantly
age-related because the magnitude of change was similar regard-
less of metabolic phenotype. HbA1c values increased signiﬁcantly
in all women over 5 years, which is a known effect of age even in
nondiabetic populations (Pani et al., 2008). In addition, nearly all
women had a signiﬁcant longitudinal increase in HDL cholesterol
and decrease in LDL cholesterol.
Aside from the age-related changes that were apparent in all 3
clusters, the clusters signiﬁcantly differed on changes in the HOMA
score (p ¼ 0.02), ketones (p ¼ 0.01), triglycerides (p ¼ 0.003), SBP Adjusted for menopause cohort, 
randomized intervention, and education
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B
t differences between phenotypes on the 3 cognitive composite scores: global cognition,
random intervention assignment. (B) Results after adding an adjustment for education.
tiple comparisons. Abbreviations: BP, blood pressure; SEM, standard error of the mean.
Table 2
Longitudinal metabolic and cognitive change in women randomized to placebo
Within-cluster changes and pairwise comparisons p-values between clusters
Healthy metabolic High blood pressure Poor metabolic
(A) Metabolic biomarkers
Glucose (mg/dL) 0.29 (0.30) 0.42 (0.32) 0.21 (0.43) 0.48
HOMA score 0.018 (0.01) 0.025 (0.01)a,c 0.025 (0.01)a,b 0.02
Ketones (mM) 0.04 (0.01)c 0.01 (0.01) 0.02 (0.01) 0.01
HDL cholesterol (mg/dL) 1.02 (0.25)c 1.24 (0.27)c 0.59 (0.37) 0.37
LDL cholesterol (mg/dL) 2.75 (0.68)c 2.17 (0.72)c 4.82 (0.98) 0.09
Triglycerides (mg/dL) 0.01 (0.01) 0.0001 (0.01) 0.03 (0.01)a,b,c 0.003
HbA1c (%) 0.04 (0.01)c 0.05 (0.01)c 0.06 (0.01)c 0.38
Systolic blood pressure (mmHg) 0.79 (0.30)c 1.68 (0.32)a,c 0.64 (0.43)a <0.0001
Diastolic blood pressure (mmHg) 0.42 (0.19)c 1.31 (0.21)a,c 0.43 (0.28)a,b <0.0001
(B) Cognitive performance
Global cognition 0.141 (0.03)c 0.104 (0.03)c 0.163 (0.04)c 0.46
Verbal memory 0.134 (0.03)c 0.133 (0.03)c 0.138 (0.04)c 0.99
Executive functions 0.002 (0.02) 0.012 (0.02) 0.006 (0.02) 0.78
(A) Average (SEM) longitudinal change per year for each metabolic biomarker within each phenotype. Changes in HOMA, ketones, and triglycerides are expressed as log values
because of a skewed distribution of values within the population. (B) Average (SEM) longitudinal change per year for each cognitive composite score within each phenotype.
Data were analyzed usingmixed effects linear models. The regression coefﬁcient for time (years) since randomization estimated the slope of metabolic and/or cognitive change
(in units/year). The TukeyeKramer method was used to adjust for multiple comparisons.
Key: BP, blood pressure; HOMA, homeostatic model assessment; SEM, standard error of the mean.
a Longitudinal change is signiﬁcantly different from the healthy phenotype (p < 0.05).
b Longitudinal change is signiﬁcantly different from the high BP phenotype (p < 0.05).
c Signiﬁcant longitudinal change from baseline (p < 0.05).
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phenotype showed a slight but signiﬁcant increase in SBP (p ¼
0.009) and DBP (p ¼ 0.031). Women in the high BP phenotype had
an increase in the HOMA score (p¼ 0.025) but a signiﬁcant decrease
in both SBP (p < 0.0001) and DBP (p < 0.0001). Women in the poor
metabolic phenotype had a signiﬁcant decrease in their triglyceride
levels (p ¼ 0.001).
With respect to the cognitive composite scores, women in the
healthy, high BP, and poor metabolic phenotypes had signiﬁcant
increases in global cognition and verbal memory (all p < 0.05),
with no signiﬁcant change in executive functions (Table 2B). The
increases in global cognition and verbal memory were likely a
learning effect as they were seen in all groups. The magnitude of
cognitive change did not signiﬁcantly differ between metabolic
phenotypes.Table 3
Longitudinal metabolic and cognitive change in women randomized to hormone therapy
Within-cluster changes and pairwise c
Healthy metabolic High b
(A) Metabolic biomarkers
Glucose (mg/dL) 0.16 (0.21) 0.
HOMA score 0.01 (0.01) 0
Ketones (mM) 0.03 (0.01)c 0
HDL cholesterol (mg/dL) 1.28 (0.25)c 1.4
LDL cholesterol (mg/dL) 3.48 (0.67)c 5
Triglycerides (mg/dL) 0.03 (0.01)c 0.0
HbA1c (%) 0.03 (0.01)c 0.0
Systolic blood pressure (mmHg) 0.32 (0.28) 1.
Diastolic blood pressure (mmHg) 0.35 (0.20) 1.
(B) Cognitive performance
Global cognition 0.114 (0.03)c 0.1
Verbal memory 0.080 (0.03)c 0.0
Executive functions 0.003 (0.02) 0
(A) Average (SEM) longitudinal change per year for each metabolic biomarker within each
because of a skewed distribution of values within the population. (B) Average (SEM) long
Data were analyzed usingmixed effects linear models. The regression coefﬁcient for time (
(in units/year). The TukeyeKramer method was used to adjust for multiple comparisons
Key: BP, blood pressure; HOMA, homeostatic model assessment; SEM, standard error of
a Longitudinal change is signiﬁcantly different from the healthy phenotype (p < 0.05)
b Longitudinal change is signiﬁcantly different from the high BP phenotype (p < 0.05)
c Signiﬁcant longitudinal change from baseline (p < 0.05).3.4. Longitudinal metabolic and cognitive changes among women
randomized to HT
In mixed effects models, women in all 3 metabolic phenotypes
randomized to HT showed a signiﬁcant increase in HbA1c
and HDL cholesterol and a signiﬁcant decrease in LDL cholesterol
(Table 3A). Further, all phenotypes showed a signiﬁcant decrease
in ketones. The clusters signiﬁcantly differed on changes in
the HOMA score (p ¼ 0.02), triglycerides (p < 0.0001), SBP
(p < 0.0001), and DBP (p < 0.0001). Women in the healthy
phenotype showed a signiﬁcant increase in triglycerides (p< 0.05;
The Writing Group for the PEPI Trial, 1995). Women in the high BP
phenotype had a signiﬁcant decrease in both SBP (p < 0.0001) and
DBP (p < 0.0001), similar to those randomized to placebo. Women
in the poor metabolic phenotype had a signiﬁcant longitudinalomparisons p-values between clusters
lood pressure Poor metabolic
18 (0.21) 0.08 (0.30) 0.96
.01 (0.01) 0.05 (0.02)a,c 0.02
.03 (0.01)c 0.03 (0.01)c 1.00
8 (0.26)c 1.70 (0.37)c 0.63
.16 (0.70)c 6.12 (0.99)a,c 0.06
04 (0.01)a 0.03 (0.01)a,b,c <0.0001
3 (0.01)c 0.03 (0.01)c 0.90
72 (0.29)a,c 0.81 (0.41)a,c <0.0001
56 (0.21)a,c 0.41 (0.29)a,b <0.0001
18 (0.03)c 0.117 (0.04)c 0.99
78 (0.03)c 0.071 (0.04) 0.98
.013 (0.02) 0.019 (0.03) 0.58
phenotype. Changes in HOMA, ketones, and triglycerides are expressed as log values
itudinal change per year for each cognitive composite score within each phenotype.
years) since randomization estimated the slope of metabolic and/or cognitive change
.
the mean.
.
.
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0.005), and SBP (p ¼ 0.05).
A general improvement in cognitive performance was also
observed in women randomized to HT (Table 3B). Women in all 3
metabolic phenotypes showed signiﬁcant increases in global
cognition (all p < 0.05), and women in the healthy and high BP
phenotypes had a signiﬁcant increase in verbal memory (both
p < 0.05). Again, this can likely be attributed to a learning effect.
There was no signiﬁcant change in executive functions, and the
magnitude of cognitive change did not signiﬁcantly differ between
metabolic phenotypes.
3.5. Treatment comparisons on longitudinal metabolic and
cognitive changes by cluster groups
On mixed effects models, there were no signiﬁcant cluster by
treatment interactions on the longitudinal trajectory of any meta-
bolic biomarker (Table 4B). A pairwise comparison of placebo and
HT within the healthy phenotype indicated that women on HT had
a signiﬁcantly greater increase in triglycerides than women on
placebo (p ¼ 0.018; Table 4A). Within the high BP phenotype,
women on HT had a greater decline in the HOMA score (p ¼ 0.017)
and LDL cholesterol (p ¼ 0.004), indicating that high BP women
randomized to HT experienced a metabolic beneﬁt (Table 4A).
Within the poor metabolic phenotype, women on HT had a greater
increase in HDL cholesterol (p ¼ 0.031) and a smaller increase in
HbA1c (p ¼ 0.048), indicating that HT was also of metabolic beneﬁt
to these women (Table 4A).
Pairwise comparisons revealed no signiﬁcant differences in the
magnitude of cognitive composite score change between women
randomized to placebo and HT within the 3 phenotypes (Table 4A).
There was no signiﬁcant cluster by treatment interaction on the
longitudinal trajectory of any of the cognitive composite scores
(Table 4B).
3.6. Metabolic biomarkers and cognition at study end among
women randomized to placebo
At the end of the study, signiﬁcant differences remained
between women in the healthy, high BP, and poor metabolic phe-
notypes on glucose (p < 0.0001), the HOMA score (p < 0.0001),
HDL cholesterol (p < 0.0001), triglycerides (p < 0.0001), HbA1cTable 4
Longitudinal cluster by treatment interaction effects on longitudinal change in metaboli
(A) Pairwise comparisons
Healthy metabolic: HT versus placebo High BP
HT effect (SEM) p-value HT effec
Metabolic biomarkers
Glucose (mg/dL) 0.126 (0.36) 0.73 0.23
HOMA score 0.010 (0.01) 0.47 0.03
Ketones (mM) 0.016 (0.01) 0.21 0.02
HDL cholesterol (mg/dL) 0.275 (0.35) 0.43 0.270
LDL cholesterol (mg/dL) 0.733 (0.96) 0.44 2.96
Triglycerides (mg/dL) 0.024 (0.01) 0.019 0.005
HbA1c (%) 0.010 (0.01) 0.35 0.01
Systolic blood pressure (mmHg) 0.460 (0.41) 0.26 0.03
Diastolic blood pressure (mmHg) 0.076 (0.28) 0.78 0.26
Cognitive performance
Global cognition 0.028 (0.05) 0.48 0.015
Verbal memory 0.053 (0.04) 0.16 0.05
Executive functions 0.001 (0.03) 0.96 0.000
(A) Pairwise comparisons of the magnitude of longitudinal change between women ran
Data are presented as estimate (SEM). (B) Cluster by treatment interaction effect on the lon
Key: BP, blood pressure; HOMA, homeostatic model assessment; HT, hormone therapy;(p < 0.0001), SBP (p < 0.0001), and DBP (p < 0.0001; Table 5A).
Women in the high BP phenotype only remained signiﬁcantly
different from women in the healthy phenotype on 4 biomarkers
(HOMA score, HDL cholesterol, SBP, and DBP, all p< 0.05; Table 4A);
women in the poor metabolic phenotype remained signiﬁcantly
different from women in the healthy phenotype on 7 biomarkers
(glucose, HOMA score, HDL cholesterol, triglycerides, HbA1c, SBP,
and DBP, all p < 0.05; Table 5A).
Cognitive composite scores did not differ betweenwomen in the
3 metabolic phenotypes for global cognition (p ¼ 0.61), verbal
memory (p ¼ 0.79), and executive functions (p ¼ 0.29) at the end of
the study (Table 5B).
3.7. Metabolic biomarkers and cognition at study end among
women randomized to HT
At the end of the study, signiﬁcant differences remained
between women randomized to HT in the healthy, high BP, and
poor metabolic phenotypes on glucose (p < 0.0001), the HOMA
score (p < 0.0001), HDL cholesterol (p < 0.0001), triglycerides
(p < 0.0001), HbA1c (p < 0.0001), SBP (p < 0.0001), and DBP
(p ¼ 0.0004; Table 6A). Women in the high BP phenotype only
remained signiﬁcantly different from women in the healthy
phenotype on SBP and DBP (both p < 0.05, Table 6A), but women in
the poor metabolic phenotype remained signiﬁcantly different
from women in the healthy phenotype on 7 biomarkers (glucose,
HOMA score, HDL cholesterol, triglycerides, HbA1c, SBP, and DBP, all
p < 0.05; Table 6A).
Cognitive composite scores did not differ betweenwomen in the
3 metabolic phenotypes for global cognition (p ¼ 0.50), verbal
memory (p ¼ 0.10), and executive functions (p ¼ 0.59) at the end of
the study (Table 6B). A pairwise comparison revealed that verbal
memory was slightly but nonsigniﬁcantly higher in healthy
compared to poormetabolic women randomized to HTat study end
(p ¼ 0.067).
3.8. Treatment comparisons on metabolic biomarkers and cognitive
composite scores at study end
There were no signiﬁcant cluster by treatment interactions for
any metabolic biomarkers at study end (Table 7). There were also no
signiﬁcant cluster by treatment interactions on the cognitivec biomarkers and cognitive composite scores
(B) Cluster treatment
interaction p-value
: HT versus placebo Poor metabolic: HT versus placebo
t (SEM) p-value HT effect (SEM) p-value
9 (0.38) 0.53 0.280 (0.53) 0.60 0.73
7 (0.02) 0.017 0.021 (0.02) 0.32 0.46
2 (0.01) 0.10 0.010 (0.02) 0.58 0.11
(0.37) 0.46 1.098 (0.51) 0.031 0.35
2 (1.01) 0.004 1.311 (1.40) 0.35 0.26
(0.01) 0.65 0.003 (0.01) 0.84 0.33
3 (0.01) 0.26 0.031 (0.02) 0.049 0.53
5 (0.43) 0.94 0.178 (0.60) 0.77 0.77
5 (0.29) 0.36 0.023 (0.40) 0.95 0.82
(0.04) 0.71 0.046 (0.06) 0.42 0.63
6 (0.04) 0.16 0.065 (0.06) 0.24 0.98
8 (0.02) 0.97 0.012 (0.03) 0.73 0.95
domized to HT and those randomized to placebo within each metabolic phenotype.
gitudinal trajectory of the 9 metabolic biomarkers and 3 cognitive composite scores.
SEM, standard error of the mean.
Table 5
Study end metabolic and cognitive values in women randomized to placebo
Pairwise comparisons Main effect of cluster at study end
Healthy metabolic High blood pressure Poor metabolic
(A) Metabolic biomarkers
Glucose (mg/dL) 81.23 (1.05) 81.37 (1.14) 91.53 (1.58)a,b <0.0001
HOMA score 0.04 (0.06) 0.20 (0.06)a 0.79 (0.09)a,b <0.0001
Ketones (mM) 2.36 (0.04) 2.40 (0.04) 2.38 (0.06) 0.80
HDL cholesterol (mg/dL) 80.14 (2.00) 69.24 (2.18)a 56.96 (3.01)a,b <0.0001
LDL cholesterol (mg/dL) 118.94 (3.53) 122.27 (3.85) 120.84 (5.32) 0.81
Triglycerides (mg/dL) 4.41 (0.04) 4.53 (0.05) 4.84 (0.06)a,b <0.0001
HbA1c (%) 5.77 (0.04) 5.64 (0.05) 6.12 (0.07)a,b <0.0001
Systolic blood pressure (mmHg) 108.22 (1.27) 117.47 (1.38)a 118.32 (1.91)a <0.0001
Diastolic blood pressure (mmHg) 69.23 (0.78) 75.27 (0.85)a 73.71 (1.17)a <0.0001
(B) Cognitive performance
Global cognition 0.71 (0.18) 0.45 (0.20) 0.57 (0.28) 0.61
Verbal memory 0.51 (0.13) 0.55 (0.14) 0.38 (0.20) 0.79
Executive functions 0.14 (0.14) 0.17 (0.15) 0.11 (0.21) 0.29
(A) Average (SEM) value at study end for each metabolic biomarker within each phenotype. HOMA, ketones, and triglycerides are expressed as log values due to a skewed
distribution of values within the population. (B) Average (SEM) value at study end for each cognitive composite score within each phenotype.
ANCOVA was used to test for overall cross-sectional differences among metabolic clusters on each biomarker and cognitive composite score. The Tukey-Kramer method was
used to adjust for multiple comparisons.
Key: HOMA, homeostatic model assessment; SEM, standard error of the mean.
a Longitudinal change is signiﬁcantly different from the healthy phenotype (p < 0.05).
b Longitudinal change is signiﬁcantly different from the high BP phenotype (p < 0.05).
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individual cognitive tests revealed an interaction effect of treatment
by cluster on the Trails-B test (p ¼ 0.041). In the healthy phenotype,
women randomized to HT performed the test an average of 6 sec-
onds slower than women randomized to placebo. This was signiﬁ-
cantly different from high BP (p¼ 0.037), where women randomized
to HT performed the test an average of 9 seconds faster thanwomen
randomized to placebo and poor metabolic, (p ¼ 0.035), where
women randomized to HT performed the test an average of 15 sec-
onds faster than women randomized to placebo (data not shown).
4. Discussion
Using a set of 9 clinically accessible biomarkers, we identiﬁed
metabolically distinct groups of women within a population char-
acterized as healthy (speciﬁcally excluding individuals withTable 6
Study end metabolic and cognitive values in women randomized to HT
Pairwise comparisons
Healthy metabolic High blood
(A) Metabolic biomarkers
Glucose (mg/dL) 81.42 (0.98) 80.07
HOMA Score 0.12 (0.05) 0.01 (
Ketones (mM) 2.35 (0.04) 2.43
HDL cholesterol (mg/dL) 79.28 (1.86) 74.19
LDL cholesterol (mg/dL) 112.91 (3.37) 120.38
Triglycerides (mg/dL) 4.46 (0.04) 4.54 (
HbA1c (%) 5.67 (0.03) 5.65 (
Systolic blood pressure (mmHg) 108.23 (1.31) 117.19
Diastolic blood pressure (mmHg) 69.47 (0.80) 73.46 (
(B) Cognitive performance
Global cognition 0.89 (0.18) 0.87 (
Verbal memory 0.84 (0.15) 0.47 (
Executive functions 0.23 (0.13) 0.32 (
(A) Average (SEM) value at study end for each metabolic biomarker within each phenotyp
distribution of values within the population. (B) Average (SEM) value at study end for e
ANCOVA was used to test for overall cross-sectional differences among metabolic cluster
used to adjust for multiple comparisons.
Key: HOMA, homeostatic model assessment; HT, hormone therapy; SEM, standard error
a Longitudinal change is signiﬁcantly different from the healthy phenotype (p < 0.05)
b Longitudinal change is signiﬁcantly different from the high BP phenotype (p < 0.05)cardiovascular disease or diabetes). The data indicate wide vari-
ability on each biomarker within this study population that was
selected for positive health. However, the variability within this
population indicated multiple phenotypes: one met criteria for
healthy metabolism, whereas two were at the margins of healthy.
Evaluating only one indicator of metabolic health would not have
provided such a robust identiﬁcation of phenotypes of risk because
even the individuals that fell within the poor metabolic cluster had
mean values at the margin of normal. Thus, in the preclinical
transition to disease, multiple indicators may have a higher prob-
ability of identifying at-risk individuals.
Within the women randomized to placebo, those in the healthy
phenotype showed a slight but signiﬁcant decline in metabolic
health over the 5-year trial. However, themetabolic declinewas not
reﬂected in cognitive performance. Thus, women in this phenotype
provide a representation of low-risk aging. In the high BPMain effect of cluster at study end
pressure Poor metabolic
(1.05) 93.66 (1.50)a,b <0.0001
0.06) 0.75 (0.08)a,b <0.0001
(0.04) 2.46 (0.06) 0.24
(1.99) 55.99 (2.82)a,b <0.0001
(3.61) 115.24 (5.13) 0.31
0.05) 4.89 (0.07)a,b <0.0001
0.04) 5.95 (0.05)a,b <0.0001
(1.40)a 116.87 (1.98)a <0.0001
0.86)a 74.30 (1.22)a 0.0004
0.19) 0.52 (0.27) 0.50
0.16) 0.34 (0.22) 0.10
0.14) 0.07 (0.19) 0.59
e. HOMA, ketones, and triglycerides are expressed as log values because of a skewed
ach cognitive composite score within each phenotype.
s on each biomarker and cognitive composite score. The Tukey-Kramer method was
of the mean.
.
.
Table 7
Study end cluster by treatment interaction effects on metabolic biomarkers and cognitive composite scores
(A) Pairwise comparisons (B) Cluster treatment
interaction p-value
Healthy metabolic: HT versus placebo High BP: HT versus placebo Poor metabolic: HT versus placebo
HT effect (95% CI) p-value HT effect (95% CI) p-value HT effect (95% CI) p-value
Metabolic biomarkers
Glucose (mg/dL) 0.034 (4.11, 4.17) 1.00 1.419 (5.86, 3.02) 0.94 2.148 (4.07, 8.36) 0.92 0.41
HOMA score 0.082 (0.31, 0.14) 0.90 0.196 (0.44, 0.05) 0.20 0.042 (0.38, 0.30) 1.00 0.49
Ketones (mM) 0.016 (0.14, 0.18) 1.00 0.020 (0.19, 0.15) 1.00 0.078 (0.32, 0.16) 0.94 0.65
HDL cholesterol (mg/dL) 0.707 (8.57, 7.15) 1.00 5.157 (3.28, 13.59) 0.50 0.469 (12.27, 11.33) 1.00 0.30
LDL cholesterol (mg/dL) 6.59 (20.64, 7.45) 0.76 2.44 (17.52,12.63) 1.00 6.092 (27.19, 15.00) 0.96 0.83
Triglycerides (mg/dL) 0.044 (0.13, 0.22) 0.98 0.010 (0.17, 0.19) 1.00 0.058 (0.20, 0.31) 0.99 0.89
HbA1c (%) 0.105 (0.27, 0.06) 0.44 0.015 (0.16, 0.19) 1.00 0.172 (0.42, 0.07) 0.34 0.16
Systolic blood pressure (mmHg) 0.174 (5.05, 5.40) 1.00 0.101 (5.71, 5.51) 1.00 1.222 (9.07, 6.63) 1.00 0.91
Diastolic blood pressure (mmHg) 0.126 (3.09, 3.34) 1.00 1.907 (5.36, 1.54) 0.61 0.565 (4.26, 5.39) 1.00 0.36
Cognitive performance
Global cognition 0.022 (0.71, 0.76) 1.00 0.263 (0.53, 1.05) 0.93 0.214 (1.33, 0.90) 0.99 0.59
Verbal memory 0.222 (0.35, 0.79) 0.87 0.168 (0.78, 0.44) 0.97 0.106 (0.97, 0.75) 1.00 0.37
Executive functions 0.057 (0.59, 0.48) 1.00 0.340 (0.23, 0.91) 0.53 0.052 (0.76, 0.86) 1.00 0.34
(A) Pairwise comparisons of values at study end between women randomized to HT and those randomized to placebo within each metabolic phenotype. Data are presented as
estimate (95% conﬁdence interval). (B) Cluster by treatment interaction effect on the study end values of the 9 metabolic biomarkers and 3 cognitive composite scores.
Key: BP, blood pressure; CI, conﬁdence interval; HOMA, homeostatic model assessment; HT, hormone therapy.
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of the trial. This could be explained by initiation of BP medication:
15 women in the high BP phenotype initiated medication to control
their blood pressure, compared with 6 healthy women and 5 poor
metabolic women. Women in the poor metabolic phenotype
remained more metabolically stable, only showing a notable
decrease in triglycerides. Women in both the high BP and poor
metabolic phenotypes had a longitudinal increase in cognitive
performance comparable to women in the healthy phenotype.
Although not statistically signiﬁcant, women in the healthy and
high BP phenotypes trended toward becoming less healthy during
the course of the trial, whereas women in the poor metabolic
phenotype trended toward becoming healthier (Tables 2 and 3). It is
possible that women with a poor metabolic phenotype received a
greater beneﬁt from the increased awareness of their health and
lifestyle derived from participating in the clinical trial relative to
healthy or high BP women. However, the poor metabolic women
did not reach a state of metabolic health comparable to the healthy
women (Table 5). Further, although individual biomarkers showed
ﬂuctuations at each trial visit, the 3 metabolic phenotypes were
very stable over the 5-year trial period. These results highlight the
power of using a panel of biomarkers: by doing so, we were able to
measure overall systemic change rather than focusing on change
within one individual biomarker.
In postmenopausal women, diabetes is associated with a lon-
gitudinal decline in cognitive function, and previous research has
shown that randomization to HT provides some protection against
conversion to diabetes (Bonds et al., 2006; Espeland et al., 2011;
Margolis et al., 2004). In the present study, randomization to HT
provided the greatest metabolic beneﬁt to women in the poor
metabolic phenotype, as these women showed improvements on
nearly every biomarker. Although randomization to HT provided no
overall cognitive beneﬁt as measured by the cognitive composite
scores, the Trails-B test results indicate that HT ameliorated meta-
bolic effects on executive function for women in the high BP and
poor metabolic phenotypes. Thus, although HT provided little
metabolic or cognitive beneﬁt to women within the healthy
metabolic cluster, it providedmetabolic beneﬁt towomen classiﬁed
as poor metabolic and some cognitive beneﬁt to women classiﬁed
as either high BP or poor metabolic.
The study results highlight the association between ethnicity,
metabolic status, and disease risk, consistent with previous studies
(Mayeda et al., 2013; O’Bryant et al., 2013; Zeki Al Hazzouri et al.,2012). Although the phenotypes were driven solely by metabolic
values and derived independently of race, there was a signiﬁcant
difference in the clusters’ racial composition. Epidemiologic data
indicate that at nearly every age, African Americans and Hispanics
have a higher risk of dementia than Caucasians (Barnes and Bennett,
2014; Seshadri et al., 1997). The impact of ethnicity may be due to
several factors, including genetically determined metabolism (Fitten
et al., 2014; Kenney et al., 2014) and differences in quality of edu-
cation (Carvalho et al., 2015). Ethnicity also plays a more general role
in lifestyle factors such as nutrition and exercise habits, which may
further impact metabolic phenotype (Sheikh and Sharma, 2014).
Although the average age at Alzheimer’s diagnosis is approxi-
mately 75 years (Holmans et al., 2005), the prodromal and/or
preclinical state of disease begins decades before diagnosis
(Sperling et al., 2011), suggesting large populations of people at risk
between approximately 55 and 75 years of age. The systems biology
approach underlying the development of peripheral-based meta-
bolic biomarkers described herein provides a rapid, clinically
deployable strategy to identify persons who may be at risk for later
development of cognitive decline and potentially AD. This approach
uses well-established clinical indicators of metabolic function that,
when combined, provide a strategy for early detection of risk within
a population. The strength of this approach is the ability to identify
persons who would be considered normal on a single indicator, but
who fall at the margin on multiple indicators, indicative of
approaching a transition state to abnormal function. The weakness
of this approach is the potential for false positives. However, a false
positive can be clinically monitored for reversal of an at-risk
phenotype. Moreover, this biomarker set could be used to detect
the impact of metabolic interventions. Conﬁrmation of the validity
of this biomarker set in persons who transition to mild cognitive
impairment or early AD is a critical next step.
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